Precision Medicine for Myalgic Encephalomyelitis
Drug Discovery and ClinicaI Trials (REMEDIAL)

We conducted a comprehensive analysis and found 27 circulating microRNAs that were significantly different in people with ME/CFS and POTS (postural orthostatic tachycardia syndrome) compared to those with ME/CFS alone or POTS alone.

• We identified two microRNAs that were only elevated in patients with both ME and POTS, and two others that were elevated only in patients with POTS but not ME.
• By examining the targets of these microRNAs, we discovered new genes and proteins that could lead to new treatment options.
• We also found a potential shared mechanism between people with both ME and POTS and those with POTS alone, which involves dopamine receptors.

Cognitive assessments using BrainCheck enabled the stratification of ME/CFS patients into three distinct clusters based on cognitive response.

• These clusters led us to discover specific microRNAs associated with particular cognitive domains, which may provide insight into mechanisms underlying cognitive impairment in ME/CFS.
• Our studies have identified three key microRNAs—miR-29a-3p, miR-150-5p, and the miR-181 family—that show promising connections to cognitive function and decline in the context of ME/CFS.

Multiple manuscripts on this work are in preparation.